Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma

MN/CA9 is a cancer-related gene, frequently activated in human renal cell carcinomas (RCCs). To reveal the activation mechanism, we investigated the relationship between methylation status of the MN/CA9 promoter region and gene expression using 13 human RCCs, and examined the effect of in vitro CpG methylation on the MN/CA9 promoter activity using a human RCC cell line (SK-RC-44), expressing MN/CA9. MN/CA9 expression was evaluated by RT-PCR and observed in 10 of 13 RCCs (77%). A total of 9 out of 10 MN/CA9 -positive RCCs (90%) contained clear cell components. Methylation status of 6 CpGs in the MN/CA9 promoter region was decided by using the bisulfite genomic sequencing protocol. Out of 13 RCCs 9 (69%) showed partial hypomethylation of the CpG at –74 bp, while the other 4 RCCs and 3 normal kidney tissue samples showed complete methylation. Hypomethylation of the CpG at –74 bp was strongly correlated with MN/CA9 expression. Luciferase assay revealed that the MN/CA9 promoter activity was strongly suppressed by methylation of the CpG at –74 bp. These findings suggest that hypomethylation of the CpG at –74 bp in the MN/CA9 promoter region might play an important role in this gene activation of human RCC. © 2001 Cancer Research Campaign http://www.bjcancer.com

[1]  J. Pastorek,et al.  P53 tumour suppressor modulates transcription of the TATA-less gene coding for the tumour-associated carbonic anhydrase MN/CA IX in MaTu cells. , 2000, Biochimica et biophysica acta.

[2]  R. Brakenhoff,et al.  Molecular cloning and immunogenicity of renal cell carcinoma‐associated antigen G250 , 2000, International journal of cancer.

[3]  T. Ohnishi,et al.  Activation of the MN/CA9 gene is associated with hypomethylation in human renal cell carcinoma cell lines , 2000, Molecular carcinogenesis.

[4]  F. Dequiedt,et al.  Transcriptional Regulation of the MN/CA 9 Gene Coding for the Tumor-associated Carbonic Anhydrase IX , 1999, The Journal of Biological Chemistry.

[5]  S. Saga,et al.  MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas , 1999, British Journal of Cancer.

[6]  Y. Konishi,et al.  Hypomethylation of CpG Sites and c‐myc Gene Overexpression in Hepatocellular Carcinomas, but Not Hyperplastic Nodules, Induced by a Choline‐deficient L‐Amino Acid‐defined Diet in Rats , 1999, Japanese journal of cancer research : Gann.

[7]  M. Rubin,et al.  The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase–polymerase chain reaction assay for MN/CA9 , 1999, Cancer.

[8]  K. Ohshima,et al.  Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. , 1998, Blood.

[9]  H. Ohtsu,et al.  Mast Cell-/Basophil-specific Transcriptional Regulation of Human l-Histidine Decarboxylase Gene by CpG Methylation in the Promoter Region* , 1998, The Journal of Biological Chemistry.

[10]  M. Wei,et al.  Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Pastorek,et al.  Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. , 1998, The American journal of pathology.

[12]  P. Jones,et al.  Involvement of DNA methylation in human carcinogenesis. , 1998, Biological chemistry.

[13]  E. Stanbridge,et al.  Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. , 1997, Cancer research.

[14]  R. Odze,et al.  MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. , 1997, Human pathology.

[15]  P. Jones,et al.  Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. , 1997, Carcinogenesis.

[16]  P. Davies,et al.  Regulation of the expression of the tissue transglutaminase gene by DNA methylation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  O. de Backer,et al.  The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Kettmann,et al.  Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. , 1996, Genomics.

[19]  S. Hirohashi,et al.  Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[21]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Kettmann,et al.  Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. , 1994, Oncogene.

[23]  John Calvin Reed,et al.  bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. , 1993, Blood.

[24]  S. Henikoff.  Unidirectional digestion with exonuclease III in DNA sequence analysis. , 1987, Methods in enzymology.

[25]  D. Ruiter,et al.  Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidney , 1986, International journal of cancer.

[26]  J. Hurst,et al.  DNA methylation and the regulation of globin gene expression , 1983, Cell.